相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
Michael E. Rytting et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination
Hanna IJspeert et al.
BLOOD (2016)
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J. Short et al.
BLOOD (2016)
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Nitin Jain et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Hyper-CVAD Plus Ponatinib Versus Hyper-CVAD Plus Dasatinib as Frontline Therapy for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis
Koji Sasaki et al.
CANCER (2016)
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples
Benjamin Y. Lu et al.
LEUKEMIA & LYMPHOMA (2016)
Adult Acute Lymphoblastic Leukemia
Shilpa Paul et al.
MAYO CLINIC PROCEEDINGS (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2015)
Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine
Stephen P. Hunger et al.
BLOOD (2015)
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Jacques J. M. van Dongen et al.
BLOOD (2015)
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Nathalie Dhedin et al.
BLOOD (2015)
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre-B-ALL
Aradhana Awasthi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Farhad Ravandi et al.
CANCER (2015)
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Elias Jabbour et al.
CANCER (2015)
Acute Lymphoblastic Leukemia, Version 2.2015
Joseph C. Alvarnas et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Characterization of CD22 Expression in Acute Lymphoblastic Leukemia
Nirali N. Shah et al.
PEDIATRIC BLOOD & CANCER (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia
Jessica Nordlund et al.
CLINICAL EPIGENETICS (2015)
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels
Daniela Bressanin et al.
Oncotarget (2015)
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia
Michael J. Burke et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Safety and clinical activity of 5-aza-2′-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia
Christopher B. Benton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia
Anjali S. Advani et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Epigenetic deregulation in pediatric acute lymphoblastic leukemia
Zac Chatterton et al.
EPIGENETICS (2014)
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function
Vania Coelho et al.
BLOOD (2013)
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
Farhad Ravandi et al.
BLOOD (2013)
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Hagop Kantarjian et al.
CANCER (2013)
The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia
Hernan Carol et al.
CLINICAL CANCER RESEARCH (2013)
Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia
David M. Barrett et al.
HUMAN GENE THERAPY (2013)
High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Linda Holmfeldt et al.
NATURE GENETICS (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Acute Lymphoblastic Leukemia in Early Childhood as the Presenting Sign of Ataxia-Telangiectasia Variant
Bella Bielorai et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2013)
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Yoav H. Messinger et al.
BLOOD (2012)
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2012)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2012)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts et al.
CANCER CELL (2012)
Treatment of acute lymphoblastic leukemia in adults
Sujata Narayanan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Genetic modification of lymphocytes by retrovirus-based vectors
Julia D. Suerth et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis
Elaine Y. Chung et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
Robert M. Sharkey et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
DNA Methylation Analysis of Bone Marrow Cells at Diagnosis of Acute Lymphoblastic Leukemia and at Remission
Jessica Nordlund et al.
PLOS ONE (2012)
Blinatumomab: A historical perspective
Dirk Nagorsen et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
William G. Wierda et al.
BLOOD (2011)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Robin Foa et al.
BLOOD (2011)
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia
John Schindler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy
Stefan Faderl et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia
Philip Saunders et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
Pier Paolo Piccaluga et al.
LEUKEMIA & LYMPHOMA (2011)
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia
Lili Milani et al.
BLOOD (2010)
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne et al.
CLINICAL CANCER RESEARCH (2010)
High incidence of Epstein Barr virus infection in childhood acute lymphocytic lukemia: A preliminary study
S. Sehgal et al.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
Deborah A. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
W-L Zhao
LEUKEMIA (2010)
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Renato Bassan et al.
BLOOD (2009)
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
Adele K. Fielding et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia
Rosemary Sutton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2009)
Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Francoise Huguet et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
Andrew W. Pawluczkowycz et al.
JOURNAL OF IMMUNOLOGY (2009)
A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia
Larry Herrera et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2009)
Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia
L. Yanez et al.
LEUKEMIA (2009)
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia
Charles G. Mullighan et al.
NATURE GENETICS (2009)
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Dario Campana
SEMINARS IN HEMATOLOGY (2009)
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen
Ginna G. Laport et al.
BLOOD (2008)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Kimmo Porkka et al.
BLOOD (2008)
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
Wendy Stock et al.
BLOOD (2008)
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
Dan Jones et al.
CANCER (2008)
Outcome of Adults With Acute Lymphocytic Leukemia After Second Salvage Therapy
Susan O'Brien et al.
CANCER (2008)
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children's oncology group pilot study
Elizabeth A. Raetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
Vinod Pullarkat et al.
BLOOD (2008)
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann et al.
BLOOD (2007)
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
E. Tavernier et al.
LEUKEMIA (2007)
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801
Daniel J. DeAngelo et al.
BLOOD (2007)
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
Anthony V. Moorman et al.
BLOOD (2007)
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Charles G. Mullighan et al.
NATURE (2007)
DNA methylation as a therapeutic target in cancer
Jean-Pierre J. Issa
CLINICAL CANCER RESEARCH (2007)
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment:: data from the GMALL 06/99 and 07/03 trials
Thorsten Raff et al.
BLOOD (2007)
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
Adele K. Fielding et al.
BLOOD (2007)
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C. Widdison et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
TM Horton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
JM Rowe et al.
BLOOD (2005)
Adult acute lymphoblastic leukemia
EJ Jabbour et al.
MAYO CLINIC PROCEEDINGS (2005)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
DA Thomas et al.
BLOOD (2004)
Outcome of treatment in adults with acute lymphoblastic leukemia:: Analysis of the LALA-94 trial
X Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase I study of bortezomib in refractory or relapsed acute leukemias
J Cortes et al.
CLINICAL CANCER RESEARCH (2004)
Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high-dose etoposide: A 15-year experience
CHM Jamieson et al.
EXPERIMENTAL HEMATOLOGY (2003)
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -: results of the prospective multicenter LALA-94 trial
H Dombret et al.
BLOOD (2002)
Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment
JM Chessells et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2001)
CD19-dependent activation of Akt kinase in B-lymphocytes
DC Otero et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
S Faderl et al.
LEUKEMIA & LYMPHOMA (2000)
分享论文
